Form 4: TransMedics Director Edward M. Basile Sells Shares Under 10b5-1 Trading Plan

Director Edward M. Basile of TransMedics Group, Inc. executed multiple sales of common stock on May 7, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On May 7, 2024, Edward M. Basile, a director of TransMedics Group, Inc., sold shares of common stock.
• The sales were executed under a Rule 10b5-1 trading plan established on September 6, 2023.
• A total of 7,157 shares were sold in multiple transactions at prices ranging from $127.89 to $132.45.
• The director still directly owns 1,193 shares of common stock after the reported transactions.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock sales by a company director under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment.

Industry Context

This Form 4 filing is a routine disclosure of stock transactions by a company insider and is a common occurrence in publicly traded companies. The use of a 10b5-1 trading plan suggests the sales were pre-planned and not based on any specific non-public information.

Stakeholder Impact

• The stock sale by a director could have a minor impact on shareholder sentiment, but the existence of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates